The power and uniqueness of AIMM’s approach rests on our ability to immortalize the human immune system’s memory B cell repertoire by transforming these cells into long living plasmablasts. This is achieved via our proprietary platform in which the genes of the anti-apoptotic Bcl-xL and the transcriptional repressor Bcl6 molecules are retrovirally transduced into the memory B cells.
The transduced B-cell clones express the B cell receptor on their surface and secrete immunoglobulins into the culture supernatant. These attributes enable AIMM to directly select B cells from the entire B cell collection based on either antigen specificity or biological function. Transduction efficiencies approaching 90% are frequently observed, allowing the interrogation of the entire human B cell repertoire. This, combined with functional testing or affinity-based selection, enables the rapid selection of cancer-specific B-cells from the entire B cell population.
AIMM has successfully deployed its AIMSelect platform to immortalize the complete B cell antibody repertoire, including immature, switched and hypermutated B cells. Most notably, our platform was clinically validated by the identification of D25, an anti-RSV antibody that is currently being advanced in Phase 3 clinical trials by Medimmune/AstraZeneca as Nirsevimab (MEDI-8897). Additionally, our platform has been validated using B-cells from multiple species. The scientific rigor of the platform served as the basis for an exclusive license by Merck/Millipore to use our platform to isolate reagents and diagnostics (Zoomabs).